0
0
We have a strong start for this year. At the consolidation rate, Yoy’s income grew 23 percent supported by strong growth in both biosimilar (29 percent) and generic (19 percent). Core income before interest, tax, depreciation, and amortization (EBITDA) grew 25 percent and margin increased to 31 percent compared to 30 percent in Q1fy22 and net profit grew 71 percent to 144 Crore Hospital.
Our financial performance this quarter includes the impact of annual increases in personnel costs as well as increased input and transportation costs, in accordance with pandemic and geopolitical disorders of the global supply chain
Our three businesses are ready for the next phase of strong and sustainable growth that has been challenged for two years Pandemi Covid-19, “said Chief Executive of Biocon and Biocon Biologics Kiran Mazumdar-Shaw.
Sale of glargine in the US, and the main biosimilar in the developing market is the main driver for biological biological performance of biocon.
Director of Biogon Biogon Biologics Arun Chandavarkar said: “The initiation of global clinical trials for two monoclonal antibodies and the progress of our other pipe assets led to an increase of 120 percent in our research and investment. strong to secure our future growth.
“Our strategic alliance with the Serum Institute Life Sciences for vaccines and acquisitions of the Viatric Global Biosimilar business is on the track for closing in the second half of the calendar year.”
